Severe Back Pain in a Young Patient with Pyoderma Gangrenosum and Crohn’s Disease Controlled with Anti-tumor Necrosis Factor Therapy: Sterile Osteomyelitis by Sarah Felton et al.
CASE REPORT
Severe Back Pain in a Young Patient with Pyoderma
Gangrenosum and Crohn’s Disease Controlled
with Anti-tumor Necrosis Factor Therapy: Sterile
Osteomyelitis
Sarah Felton • Firas Al-Niaimi • Calum Lyon
To view enhanced content go to www.dermtherapy-open.com
Received: December 16, 2013 / Published online: February 5, 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Inflammatory bowel disease has
been associated with a number of cutaneous
and systemic neutrophilic disorders, including
pyoderma gangrenosum. In 1972, the term
chronic multi-focal recurrent osteomyelitis was
given to a sterile neutrophilic condition which
has been associated with inflammatory bowel
disease.
Case Report: We report a case of a 23-year-old
man with long-standing severe Crohn’s disease
which necessitated subtotal colectomy.
He subsequently developed progressive,
intermittent back pain that were limiting his
functional movement. Numerous investigations
to identify what initially was thought to be an
infectious process failed to lead to the diagnosis.
Biopsy of the spine identified a sterile
neutrophilic infiltrate and the diagnosis of
chronic recurrent multi-focal osteomyelitis was
made which was successfully treated with
immunosuppressive drugs.
Conclusion: Inflammatory bowel disease can
present with cutaneous and systemic
neutrophilic disorders and this association is
becoming increasingly recognized by
gastroenterologists and dermatologists.
Chronic recurrent multi-focal osteomyelitis is
a sterile neutrophilic disorder which can
present with bone pain and responds to
immunosuppressive therapy.
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Immuno-suppressed patients are prone to a
number of bony disorders including infective
osteomyelitis and spinal lymphoma [1]. The
authors describe their experience of the
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investigation and management of back pain in a
patient with inflammatory bowel disease (IBD)
and pyoderma gangrenosum (PG), with the
subsequent diagnosis of chronic recurrent
multi-focal osteomyelitis (CRMO). Non-
infectious causes of bone pain have been
reported in certain neutrophilic disorders and
dermatologists should be aware of this rare, but
otherwise debilitating syndrome.
CASE REPORT
A 23-year-old male patient with long-standing
Crohn’s disease, which had necessitated
subtotal colectomy, was under regular
dermatological review for the management of
hidradenitis suppurativa, perianal Crohn’s
disease and recalcitrant PG affecting the
inguinal and scrotal regions. He was treated
with a combination of topical tacrolimus
ointment at the strength of 0.3% mixed with
clobetasol ointment, oral metronidazole, oral
prednisolone and azathioprine in an attempt to
control bowel and skin symptoms. These
resulted in limited long-term benefit and
treatment with biological therapy infliximab
was considered. At the same time, the patient
also described the progressive development of
intermittent mid-back pain that did not settle
with a combination of analgesics (paracetamol,
tramadol, diazepam and ibuprofen).
Spinal X-rays had not shown any
abnormality but he was admitted acutely for
severe unrelenting back pain, and a
significantly elevated C-reactive protein (CRP)
level of 350 mg/L, which coincided with acute
worsening of the cutaneous PG. A bone scan
highlighted abnormally intense activity within
some thoracic (T) vertebrae; bone windows on
computerized tomography (CT) revealed soft
tissue thickening on T7 and T9 vertebral bodies,
with a small amount of adjacent bony lucency
related to the T9 area; magnetic resonance
imaging (MRI) demonstrated multi-level T
vertebral body abnormalities, but no soft tissue
masses, vertebral fractures or evidence of
discitis. The aforementioned features were
suggestive of spinal lymphoma or chronic
osteomyelitis. Concern was raised about the
use of anti-tumor necrosis factor (TNF)
treatments for his PG and Crohn’s disease
because of the potential for worsening what
was a possible infective osteomyelitis. A spinal
biopsy was, therefore, performed and histology
described thickened trabecular bone with
woven bone formation on polarized light, and
some osteoblastic activity. The bone marrow in
some areas was fibrotic with small thin-walled
vessels, but there was no granulomatous
inflammation or evidence of neoplasia.
Appearances were in keeping with chronic,
non-specific osteomyelitis, but cultures from
biopsy material were negative for bacteria,
mycobacteria and fungi. The clinical
presentation and absence of microbiological
agents led to the diagnosis of CRMO.
Once infection had been excluded, the
patient was treated with prednisolone and
azathioprine, while awaiting anti-TNF therapy.
Infliximab substantially improved skin and
bowel symptoms. In addition, two subsequent
spinal MRI scans at 9 and 18 months have
shown resolution of the signal changes within
the vertebral bodies, coinciding with marked
resolution of the clinical symptoms of back
pain.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
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DISCUSSION
The term CRMO was first described in 1972 as
an unusual form of multi-focal bone lesions
encompassing subacute and chronic
symmetrical osteomyelitis [1, 2]. It is
characterized by self-limiting but relapsing
episodes of non-infectious osteomyelitis.
Although of unknown etiology, CRMO has
recognized association with a number of
dermatoses, particularly the neutrophilic
dermatoses of PG, Crohn’s and Sweet’s
syndrome [3, 4]. Its association with IBD was
first reported in 1998 [5], and the diagnosis may
precede the development of bowel symptoms
by around 5 years [6]. More recently, it has been
suggested that CRMO may represent a pediatric
form of SAPHO (synovitis, acne, pustulosis,
hyperostosis, osteitis), and should be
considered as an auto-inflammatory syndrome
[7].
Patients are usually children who present
with recurrent episodes of bone pain, general
malaise and raised inflammatory markers,
which may be initially misdiagnosed as
infective osteomyelitis or neoplasia [8]. The
main sites of reported involvement are the
tibia, pelvis, femur and clavicle [8]. Non-
steroidal anti-inflammatory drugs are often
used as first-line treatment with good
response. Second-line options include
bisphosphonates, systemic immunosuppressive
drugs and rarely, such as in our case, TNF
antagonists [6, 8, 9]. While oral steroids are
effective in the majority of cases they are
generally not used due to the side effects of
long-term treatment. Follow-up studies have
shown that the disease can remain active for
around 10 years, highlighting its chronic and
recurrent nature [10].
The author wishes to highlight the
increasingly recognized phenomenon of
CRMO and in particular document the
previously unreported correlation between
episodes of severe back pain and flares of PG.
It is inevitably important to consider CRMO in
the differential diagnosis of back pain as
treatment options involve immunosuppression
rather than the high-dose prolonged antibiotic
therapy required for infective osteomyelitis. In
this patient, anti-TNF therapy that was
originally instigated for control of bowel
symptoms also ameliorated PG and his back
pain due to CRMO.
CONCLUSION
In conclusion, we report a case of a young man
with the background of PG and IBD who
presented with severe back pain as part of a
rare condition of CRMO. Accurate identification
and diagnosis of this condition enables timely
treatment with minimal sequelae.
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